T. Rowe Price Associates
LBRX

T. Rowe Price Associates’s LB Pharmaceuticals LBRX Stock Holding History

T. Rowe Price Associates’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$327K Buy
13,229
+2,155
+19% +$49.7K ﹤0.01% 2645
2025
Q4 		$247K Sell
11,074
-271,570
-96% -$4.74M ﹤0.01% 2735
2025
Q3 		$4.46M Buy
+282,644
New +$4.48M ﹤0.01% 1429

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

T. Rowe Price Associates's LBRX Position: Q1 2026 in Review

T. Rowe Price Associates increased its LB Pharmaceuticals (LBRX) stake by 19% in Q1 2026, buying an estimated $49.7K and bringing the position to 13,229 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #2645.

T. Rowe Price Associates first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.46M in Q3 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • T. Rowe Price Associates held 13,229 shares of LB Pharmaceuticals worth $327K as of Q1 2026.
  • T. Rowe Price Associates bought 2,155 LB Pharmaceuticals shares in Q1 2026, an estimated $49.7K.
  • LB Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2645 holding.
  • T. Rowe Price Associates first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • T. Rowe Price Associates's LB Pharmaceuticals position peaked at $4.46M in Q3 2025.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.